Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions
Study participants may transition from the rivaroxaban arm to abelacimab in an extension study
United States John Glasspool Study Group Data Monitoring Committee Broad Institute Drug Administration
Source: dicardiology.com